Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02599649

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of this clinical research study is to learn if lirilumab and Opdivo (nivolumab), alone or in combination with Vidaza (azacitidine), can help to control MDS. The safety of these drug combinations will also be studied.

Status: 
Recruiting
Study Date: 
Tue, 03/01/2016 to Sat, 03/01/2025
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Lirilumab 3 mg/kg by vein every 4 weeks. Drug: Nivolumab 3 mg/kg by vein on Days 7 and 21 of a 28 day cycle. Other Names: BMS-936558 Opdivo Drug: Azacitidine 75 mg/m^2 by vein for 7 days of a 28 day cycle. Other Names: 5-azacytidine 5-aza Vidaza 5-AZC AZA-CR Ladakamycin NSC-102816 Azacytidine